Shanghai Kehua Bio-Engineering Co.,Ltd Stock

Equities

002022

CNE000001KC9

Medical Equipment, Supplies & Distribution

End-of-day quote Shenzhen S.E. 06:00:00 2024-05-07 pm EDT 5-day change 1st Jan Change
7.6 CNY +0.80% Intraday chart for Shanghai Kehua Bio-Engineering Co.,Ltd +3.26% -33.22%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
Sales 2022 6.97B 965M Sales 2023 2.43B 336M Capitalization 5.85B 810M
Net income 2022 971M 134M Net income 2023 -234M -32.39M EV / Sales 2022 0.54 x
Net cash position 2022 2.61B 361M Net cash position 2023 1.04B 144M EV / Sales 2023 1.98 x
P/E ratio 2022
6.79 x
P/E ratio 2023
-25 x
Employees 2,151
Yield 2022
4.85%
Yield 2023
-
Free-Float 76.41%
More Fundamentals * Assessed data
Dynamic Chart
Shanghai Kehua Bio-Engineering Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Kehua Bio-Engineering Gets Registration Certificates for Two Devices MT
Tranche Update on Shanghai Kehua Bio-Engineering Co.,Ltd's Equity Buyback Plan announced on October 29, 2023. CI
Shanghai Kehua Bio-Engineering Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Shanghai Kehua Bio-Engineering Co.,Ltd Approves Board Elections CI
Kehua Bio-Engineering Gets Nod to Register Protein Detection Kit MT
Xi'an Zhitong Benyi Enterprise Management Partnership Enterprise (Limited Partnership) completed the acquisition of 5% stake in Shanghai Kehua Bio-Engineering Co.,Ltd from Zhuhai Baolian Asset Management Co., Ltd. CI
Shanghai Kehua Bio-Engineering Gets Approval for Leucine Aminopeptidase Kit MT
Xi'an Zhitong Benyi Enterprise Management Partnership Enterprise (Limited Partnership) agreed to acquire 5% stake in Shanghai Kehua Bio-Engineering Co.,Ltd from Zhuhai Baolian Asset Management Co., Ltd. for CNY 514.3 million. CI
Tranche Update on Shanghai Kehua Bio-Engineering Co.,Ltd's Equity Buyback Plan announced on October 29, 2023. CI
Shanghai Kehua Bio-Engineering Co.,Ltd announces an Equity Buyback for CNY 200 million worth of its shares. CI
Shanghai Kehua Bio-Engineering Co.,Ltd authorizes a Buyback Plan. CI
Shanghai Kehua Bio-Engineering Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Shanghai Kehua Bio-Engineering Co.,Ltd(XSEC:002022) added to S&P Global BMI Index CI
Shanghai Kehua Bio-Engineering Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2023 CI
More news
1 day+0.80%
1 week+3.26%
Current month+3.26%
1 month-4.40%
3 months+17.65%
6 months-13.64%
Current year-33.22%
More quotes
1 week
7.40
Extreme 7.4
7.86
1 month
6.61
Extreme 6.61
7.86
Current year
6.19
Extreme 6.19
11.78
1 year
6.19
Extreme 6.19
12.44
3 years
6.19
Extreme 6.19
19.82
5 years
6.19
Extreme 6.19
25.99
10 years
6.19
Extreme 6.19
64.00
More quotes
Managers TitleAgeSince
President 48 23-04-02
Director of Finance/CFO 52 21-03-31
Director/Board Member 50 08-12-31
Members of the board TitleAgeSince
Director/Board Member 52 22-10-16
Chairman 44 22-09-20
President 48 23-04-02
More insiders
Date Price Change Volume
24-05-07 7.6 +0.80% 6 703 300
24-05-07 7.54 +0.27% 3,464,145
24-05-06 7.52 +2.17% 3,295,381
24-04-30 7.36 +0.68% 3,324,256

End-of-day quote Shenzhen S.E., May 07, 2024

More quotes
Shanghai Kehua Bio-engineering Co., Ltd. specializes in the development, manufacturing and marketing of diagnostic biological products. The group proposes primarily reagents, in vitro diagnostics agents, automated instruments of detection, etc. China accounts for 91% of net sales.
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 002022 Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW